Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
gp120 is a glycoprotein exposed on the surface of the HIV viral envelope and is essential for virus entry into host cells. It mediates attachment to specific cell surface receptors, primarily CD4 on helper T-cells, as well as coreceptors such as CCR5 or CXCR4. Binding to CD4 triggers conformational changes in both gp120 and its partner protein gp41, leading to fusion of the viral and cellular membranes. Gp120 is a major target for neutralizing antibodies but has evolved mechanisms—such as variable loops (V1–V5), heavy glycosylation, and conformational masking—to evade immune detection.
Gp120 binds to CD4 and coreceptors (CCR5 or CXCR4) to mediate HIV entry into host cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on gp120 envelope protein (HIV).